

Alessandra Gennari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2839524/publications.pdf>

Version: 2024-02-01

108
papers

6,512
citations

101543

36
h-index

66911

78
g-index

113
all docs

113
docs citations

113
times ranked

9390
citing authors

#	ARTICLE	IF	CITATIONS
1	3rd ESOâ€“ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33.	1.2	865
2	Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. Cancer Prevention Research, 2010, 3, 1451-1461.	1.5	783
3	Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine, 2016, 14, 1.	5.5	521
4	HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. Journal of the National Cancer Institute, 2008, 100, 14-20.	6.3	344
5	Survival of metastatic breast carcinoma patients over a 20-year period. Cancer, 2005, 104, 1742-1750.	4.1	253
6	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. Journal of Clinical Oncology, 2012, 30, 2593-2600.	1.6	218
7	3rd ESOâ€“ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259.	2.2	171
8	Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs. Clinical Pharmacokinetics, 2002, 41, 431-444.	3.5	168
9	Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 2011, 29, 2144-2149.	1.6	167
10	Metabolism: A Bottleneck in <i>In Vitro</i> Toxicological Test Development. ATLA Alternatives To Laboratory Animals, 2006, 34, 49-84.	1.0	161
11	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discovery, 2020, 10, 1465-1474.	9.4	151
12	Breast Cancer Survivorship, Quality of Life, and Late Toxicities. Frontiers in Oncology, 2020, 10, 864.	2.8	121
13	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Scientific Reports, 2020, 10, 20731.	3.3	96
14	Dendritic Cells as a Tool for the Predictive Identification of Skin Sensitisation Hazard. ATLA Alternatives To Laboratory Animals, 2005, 33, 47-62.	1.0	94
15	Pemetrexed: A promising new treatment for breast cancer. Seminars in Oncology, 2002, 29, 36-41.	2.2	92
16	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 127-138.	10.7	91
17	Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients. Clinical Breast Cancer, 2000, 1, 156-161.	2.4	90
18	Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.. Journal of Clinical Oncology, 1997, 15, 2510-2517.	1.6	89

#	ARTICLE	IF	CITATIONS
19	Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors. <i>Journal of Clinical Oncology</i> , 1999, 17, 3596-3602.	1.6	89
20	Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3912-3918.	1.6	85
21	Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 171-179.	2.5	82
22	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. <i>Journal of Oncology</i> , 2012, 2012, 1-8.	1.3	79
23	Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 433-442.	2.5	77
24	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	10.7	73
25	Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. <i>British Journal of Cancer</i> , 2004, 90, 962-967.	6.4	69
26	Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 31-35.	6.4	66
27	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841.	3.7	58
28	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	10.7	50
29	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 556718.	2.8	49
30	Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 919-927.	1.2	48
31	Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 508-518.	2.4	42
32	Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care. <i>Journal of Clinical Oncology</i> , 2011, 29, 7-10.	1.6	41
33	Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. <i>Annals of Oncology</i> , 1996, 7, 978-979.	1.2	40
34	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. <i>Cell Stress</i> , 2019, 3, 284-294.	3.2	40
35	Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 405-413.	2.5	38
36	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	2.8	37

#	ARTICLE	IF	CITATIONS
37	Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials. <i>Clinical Cancer Research</i> , 2016, 22, 4594-4603.	7.0	32
38	Role of Epirubicin in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2000, 1, S46-S51.	2.4	29
39	Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights. <i>Biomolecules</i> , 2021, 11, 125.	4.0	27
40	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. <i>Disease Markers</i> , 2021, 2021, 1-7.	1.3	24
41	Exemestane for Breast Cancer Prevention: A Critical Shift?. <i>Cancer Discovery</i> , 2012, 2, 25-40.	9.4	23
42	Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1862-1867.	2.5	22
43	Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia. <i>Annals of Oncology</i> , 1999, 10, S91-S94.	1.2	21
44	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 829-841.	10.5	21
45	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 79-86.	2.5	20
46	Definition of High-Risk Early Hormone-Positive HER2 ⁺ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
47	The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. <i>Breast</i> , 2011, 20, S36-S41.	2.2	19
48	Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 229-232.	3.2	19
49	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821.	2.6	19
50	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	2.8	19
51	Identification and Validation of a New Set of Five Genes for Prediction of Risk in Early Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 9686-9702.	4.1	18
52	18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. <i>Nuklearmedizin - NuclearMedicine</i> , 2015, 54, 163-172.	0.7	18
53	Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. <i>British Journal of Cancer</i> , 2005, 93, 406-411.	6.4	16
54	Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review. <i>Tumori</i> , 2011, 97, 690-692.	1.1	16

#	ARTICLE	IF	CITATIONS
55	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 61-68.	2.5	15
56	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	1.1	15
57	Breast Cancer Diet – A Review of Healthy Dietary Patterns to Prevent Breast Cancer Recurrence and Reduce Mortality. <i>Nutrients</i> , 2022, 14, 476.	4.1	14
58	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	6.3	14
59	Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II study. <i>Annals of Oncology</i> , 1996, 7, 857-860.	1.2	13
60	Anthracyclines-paclitaxel combinations in the treatment of breast cancer. <i>Annals of Oncology</i> , 1997, 8, 939-943.	1.2	13
61	New Understanding of the Role of Anthracyclines in Early-Stage Breast Cancer: Patient Selection Considerations. <i>Clinical Breast Cancer</i> , 2008, 8, S179-S183.	2.4	13
62	Association between insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) and prognosis in patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1086-1086.	1.6	13
63	Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 131-136.	2.5	12
64	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
65	Oncolytic virotherapy: new weapon for breast cancer treatment. <i>Ecancermedalscience</i> , 2020, 14, 1149.	1.1	12
66	The Hypoxic Profile during Trekking to the Pyramid Laboratory. <i>High Altitude Medicine and Biology</i> , 2009, 10, 233-237.	0.9	11
67	An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1437-1442.	2.4	11
68	Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. <i>Translational Oncology</i> , 2016, 9, 600-605.	3.7	11
69	A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. <i>Annals of Oncology</i> , 2018, 29, 661-668.	1.2	11
70	Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2137.	3.7	11
71	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	2.8	11
72	HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. <i>Bone Marrow Transplantation</i> , 2004, 34, 413-417.	2.4	10

#	ARTICLE	IF	CITATIONS
73	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016, 6, S1-S10.	0.4	10
74	SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response. <i>Journal of Medical Virology</i> , 2021, 93, 6444-6446.	5.0	10
75	Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, 743.	3.7	7
76	Weekly Docetaxel/Paclitaxel in Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2002, 3, 346-352.	2.4	6
77	Editorial: Why are guidelines not followed in clinical practice?. <i>Breast</i> , 2017, 32, 245-246.	2.2	5
78	A randomized clinical study on the impact of Comprehensive Geriatric Assessment (CGA) based interventions on the quality of life of elderly, frail, onco-hematologic patients candidate to anticancer therapy: protocol of the ONCO-Aging study. <i>BMC Geriatrics</i> , 2021, 21, 320.	2.7	5
79	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	3.2	5
80	Relationship between individual ventilatory response and acute renal water excretion at high altitude. <i>Respiratory Physiology and Neurobiology</i> , 2008, 162, 103-108.	1.6	4
81	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	3.2	4
82	Precision Medicine in Systemic Mastocytosis. <i>Medicina (Lithuania)</i> , 2021, 57, 1135.	2.0	4
83	Anthracyclines in the management of metastatic breast cancer: state of the art. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 11-15.	2.2	3
84	Whither the PET Scan? The Role of PET Imaging in the Staging and Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2012, 14, 20-26.	4.0	3
85	Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. <i>European Journal of Cancer</i> , 2021, 155, 127-135.	2.8	3
86	Metastatic Mediastinal Germ Cell Tumor and Concurrent COVID-19: When Chemotherapy Is Not Deferrable. <i>Oncologist</i> , 2021, 26, e347-e349.	3.7	3
87	Identification of a Prognostic Signature Based on the Expression of Genes Related to the Insulin Pathway in Early Breast Cancer. <i>Breast Care</i> , 2021, 16, 299-306.	1.4	2
88	Impact of the G8 score on the outcome of a cohort of elderly patients with solid or hematological malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 12038-12038.	1.6	2
89	A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2012, 5, 17.	3.0	1
90	Anthracycline-free therapy for HER2-amplified breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, 1037-1038.	10.7	1

#	ARTICLE	IF	CITATIONS
91	ERA-Net TRANSCAN JTC 2011: Critical aspects of the startup procedures of an International Academic Clinical trial (ET-FES), funded by the European Community (EC) and coordinated by an Italian Institution.. <i>Annals of Oncology</i> , 2016, 27, iv113.	1.2	1
92	Helping the cardio-oncologist: from real life to guidelines. <i>Seminars in Oncology</i> , 2019, 46, 433-436.	2.2	1
93	Impact of insulin resistance (IR) on the prognosis of metastatic breast cancer (MBC) patients treated with first-line chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 514-514.	1.6	1
94	Efficacy of CDK 4/6 inhibitors in ER positive metastatic breast cancer: Systematic review and meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13040-e13040.	1.6	1
95	ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study. <i>Frontiers in Medicine</i> , 2021, 8, 817678.	2.6	1
96	The Quality of Life Issue in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 223-224.	2.4	0
97	Case histories: breast cancer. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 36-42.	2.2	0
98	The Role of Liposomal Anthracyclines in Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013, 5, 23-30.	1.0	0
99	News from the San Antonio Breast Cancer Symposium 2014. <i>Breast Care</i> , 2015, 10, 61-64.	1.4	0
100	IN28 DURATION OF FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER. <i>Breast</i> , 2015, 24, S31.	2.2	0
101	BP129 INSULIN RESISTANCE (IR) AND PROGNOSIS OF METASTATIC BREAST CANCER (MBC) PATIENTS. <i>Breast</i> , 2015, 24, S66.	2.2	0
102	Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials. <i>Annals of Oncology</i> , 2016, 27, vi61.	1.2	0
103	Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. <i>Seminars in Oncology</i> , 2001, 28, 15-17.	2.2	0
104	Breast cancer incidence after hormonal treatments for infertility: Systematic review update.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11552-e11552.	1.6	0
105	Abstract 1182: Metformin affects breast cancer cell growth and disturbs an IGF1/insulin related gene network that correlates with breast cancer progression. <i>Cancer Research</i> , 2015, 75, 1182-1182.	0.9	0
106	Ovarian stimulation for infertility treatment and cancer risk: An Italian cohort study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 534-534.	1.6	0
107	Host metabolic factors and prognosis in patients treated with immune checkpoint inhibitors for advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14162-e14162.	1.6	0
108	PD-L1 status and efficacy of immune check-point inhibitors (ICIs) in advanced cancer patients: A pooled analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15263-e15263.	1.6	0